{
    "Trade/Device Name(s)": [
        "Elecsys CA 19-9 Immunoassay",
        "Elecsys CA 19-9 CalSet"
    ],
    "Submitter Information": "Roche Diagnostics",
    "510(k) Number": "K050231",
    "Predicate Device Reference 510(k) Number(s)": [
        "K020566"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NIG",
        "JIT"
    ],
    "Summary Letter Date": "July 6, 2005",
    "Summary Letter Received Date": "January 26, 2005",
    "Submission Date": "January 21, 2005",
    "Regulation Number(s)": [
        "21 CFR 866.6010"
    ],
    "Regulation Name(s)": [
        "Tumor-associated antigen immunological test system"
    ],
    "Analyte Class(es)": [
        "immunology",
        "cancer molecular"
    ],
    "Analyte(s)": [
        "CA 19-9 tumor associated antigen"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Roche Elecsys 1010",
        "Roche Elecsys 2010",
        "MODULAR ANALYTICS E170 (Elecsys module)"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemiluminescence immunoassay (ECLIA)",
        "Sandwich immunoassay"
    ],
    "Methodologies": [
        "Quantitative immunoassay",
        "Electrochemiluminescence detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator"
    ],
    "Document Summary": "FDA 510(k) summary for Elecsys CA 19-9 Immunoassay and CalSet for quantitative determination of CA 19-9 antigen in serum and plasma for pancreatic cancer management.",
    "Indications for Use Summary": "Quantitative measurement of CA 19-9 antigen in serum and plasma to aid in monitoring disease status and management of patients with exocrine pancreatic cancer using Roche Elecsys immunoassay systems.",
    "fda_folder": "Clinical Chemistry"
}